“The second quarter 2019 was particularly successful as we hit a key milestone and reached several key objectives as the optimization work was completed. We are continuing to ramp up towards commercializing IMMray™ PanCan-d, our diagnostic test for early detection of pancreatic cancer. At the beginning of June, we announced excellent results from IMMray™ PanCan-d’s optimization work. This study, performed in collaboration with Prof. Stephen Pereira of the University College of London, is the first ever to achieve such results where pancreatic cancer (PDAC, pancreatic ductal adenocarcinoma) is detected with high accuracy versus patients without PDAC but with non-specific concerning symptoms, including the new onset type II diabetics. This reflect very closely the clinical situation where IMMray™ PanCan–d will be used commercially. IMMray™ PanCan-d, our blood-based test for early detection of pancreatic cancer, is now set for Q3 2020 launch. In July, Immunovia presented the results of the IMMray™ PanCan-d optimization study at PancreasFest 2019 in Pittsburgh, PA, a major annual meeting of pancreas physicians and translational researchers, receiving very positive response. Additionally, during the quarter Immunovia and University College of London signed an agreement to extend validation studies of IMMray™ PanCan-d for early signs and symptoms. Professor Stephen Pereira and his team at the Institute for Liver and Digestive Health, University College London (UCL) will extend the prospective collection of blood samples funded by Immunovia and that started with the PanSYM-1 pilot study. The pilot PanSYM-1 study at UCL that started in 2017 will now support the continuation of PanSYM-1 as a prospective validation study. The continued PanSYM-1 study aims to demonstrate the diagnostic value of IMMray™ PanCan-d in detecting PDAC earlier than the current standard practice. At Immunovia, we remain fully committed and focused on the commercialization of IMMray™ PanCan-d and continue to do everything possible to maximize efficiency while maintaining our high quality. We are on schedule and continue to work intensely on the next step and all preparations for our planned launch in autumn 2020.” Excerpt from the CEO Mats Grahn’s comment on the report. Key Indicators Key April- April- Jan-June Jan-June Full Indicators June 2019 June 2018 2019 2018 year2018 (SEK thousand unless otherwise stated) Net Sales  154 44 220 156 333 Operating -29,542 -27,232 -56,738 -44,608 -87 708 earnings  Earnings -29,897 -26,147 -56,277 -43,473 -86,531 before tax  Net -29,897 -26,154 -56,280 -43,480 -86,538 earnings  Earnings per -1.53 -1.47 -2.88 -2.47 -4.67 share before dilution (SEK/share)  Earnings per -1.53 -1.47 -2.88 -2.47 -4.67 share after dilution (SEK/share)  Equity 88 96 88 96 97 ratio, %  No. of 19,531,353 19,480,853 19,531,353 19,480,853 19,531,353 shares at the end of the period  Immunovia invites to a teleconference (in English) for investors, analysts and media on August 23, at 4:00 p.m. CET. Immunovia will publish the company’s interim report for the period January-June 2019 on Friday, August 23, 2019 at 3:00 pm CET. This financial statement has been produced in accordance with IFRS for the Immunovia Group, which comprises Immunovia AB and the wholly owned subsidiaries Immunovia Incentive AB, Immunovia Inc. and Immunovia GmbH. Mats Grahn, CEO will present Immunovia and comment on the interim report for the period January-June 2019 followed by a Q&A session. Please call in a few minutes in advance. To attend, please dial-in at one of the numbers below: BE: +3226200547  CH: +41225805976 DE: +4969222220380 DK: +4578150107  FR: +33170750718  NL: +31207219496 NO: +4723500236  SE: +46850558357  UK: +443333009032  US: +18338230586 For more information, please contact:  Julie Silber, Director of Investor Relations, Immunovia Email: julie.silber@immunovia.com (http://julie.silber@immunovia.com/)  Tel: +46 7 93 486 277 There will be an MP3-file available at Immunovia’s webpage under Investors/Financial Reports (http://immunovia.com/investors/financial-reports/ (http://immunovia.com/investors/financial-reports/)) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended. About Immunovia  Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. (Source: www.immunovia.com (http://www.immunovia.com/)) This information is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above. Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com. ###